Clinical Trial Update: Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood [Phase 1]

View source ↗

Summary

Phase 1 trial update on infusing allogeneic CD19-specific T cells from peripheral blood for leukemia and lymphoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Allogeneic CD19-Specific T Cells (from peripheral blood) (CD19-targeted T cells (allogeneic))

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED